Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03272373 · ClinicalTrials.gov registry record · NA

NexGen TM Tibia Clinical Outcomes Study

A NA study of Rheumatoid Arthritis and Osteoarthritis, sponsored by Zimmer Biomet.

Completed
Registry status
NA
Development phase
160
Enrollment target
7
Study locations

NCT03272373: Completed NA study of Rheumatoid Arthritis and Osteoarthritis, sponsored by Zimmer Biomet.

NCT03272373 is a NA study of Rheumatoid Arthritis and Osteoarthritis that has completed, run by Zimmer Biomet. The registered enrollment target is 160 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03272373, a NA study of Rheumatoid Arthritis and Osteoarthritis, has completed, sponsored by Zimmer Biomet.

COMPLETED
Registry status
NA
Development phase
160 participants
Enrollment target
7
Study locations

Study Summary

The objective of this study is to evaluate clinical performance for the commercially available NexGen TM Monoblock Tibia and NexGen TM Modular Tibia used in primary cementless tibia total knee arthroplasty.

Primary Outcome

Progressive tibial radiolucency will be derived in accordance with the following definitions: Absent: No evidence of an increase in either radiolucency extent (number of zones involved) or measured width within a zone. Present: Presence of either: An increase in the number of zones with a measured tibial radiolucency, OR an increase in the measured tibial radiolucency width within a zone of \>0.5mm. Unable to assess: One or more of the component factors necessary to derive progressive tibial

Conditions Studied

Rheumatoid Arthritis Osteoarthritis Traumatic Arthritis Polyarthritis Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle Post-traumatic Loss of Joint Configuration Moderate Valgus, Varus, or Flexion Deformities

Interventions

  • DEVICE NexGen TM Monoblock Tibia
  • DEVICE NexGen TM Modular Tibia

Study Locations (7)

Indiana

  • Franciscan Health - Mooresville
  • Henry County Orthopedics and Sports Medicine - New Castle

California

  • LA BioMed at Harbor-UCLA Medical Center - Torrance

Colorado

  • Cornerstone Orthopaedics & Sports Medicine, P.C. - Wheat Ridge

Missouri

  • Woods Mill Orthopedics, Ltd - Chesterfield

North Carolina

  • Pinehurst Surgical Clinic - Pinehurst

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2017-10-03
Est. Completion 2023-03-31
Phase NA
Zimmer Biomet

115 total trials

What the finished NCT03272373 record still lists

NCT03272373 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower).

The record links to 7 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which NexGen TM Monoblock Tibia is the first listed.

NCT03272373 lists 7 locations in 6 states (Indiana, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT03272373 about?

NCT03272373 is a clinical study titled "NexGen TM Tibia Clinical Outcomes Study". The objective of this study is to evaluate clinical performance for the commercially available NexGen TM Monoblock Tibia and NexGen TM Modular Tibia used in primary cementless tibia total knee arthroplasty.

What is the current status of trial NCT03272373?

This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2017-10-03. Estimated completion is 2023-03-31.

What conditions does trial NCT03272373 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle.

What interventions are being tested in trial NCT03272373?

The interventions under investigation include: NexGen TM Monoblock Tibia (DEVICE), NexGen TM Modular Tibia (DEVICE).

Who is sponsoring clinical trial NCT03272373?

This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03272373 being conducted?

This trial has 7 study locations across California, Colorado, Indiana, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03272373's enrollment target sits among peer trials

160 94th of 197 higher than 102 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03272373, the US trial registry maintained by the National Library of Medicine. NCT03272373 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.